IGLON5 and tauopathy: The original neuropathological description in 2014 of a new hypothalamic and brainstem-predominant neuronal 3- and 4-repeat (R) tauopathy underlying anti-IgLON5 disease included two patients [49], and was followed by 4 additional cases (1 definite and 3 probable), which together set the basis for the establishment of the neuropathological research criteria of the anti-IgLON5 tauopathy in 2016 [23].